According to Seres Therapeutics, the partners will research to assess microbiome-based approaches as a predictor for which cancer immunotherapies get the best response from patients. In addition, the
This round of investment was co-led by Advantech Capital and CMBI, followed by Pudong Innotek. Also participating were existing investors Lilly Asia Venture (LAV) and OrbiMed Asia. “The
The priority review for Dupixent is for the treatment of adult patients whose CRSwNP is inadequately controlled. CRSwNP is a chronic disease of the upper airway. It is
On March 2nd, 2019, TaiwanJ announced that its JKB-122, an effective phase 2 nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) drug candidate, had been successfully licensed out to
These two studies met their primary endpoints, showing that the combination of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine, injected every four weeks, was non-inferior in maintaining viral suppression
The case report, published in Nature and carried out with partners at the University of Cambridge and the University of Oxford, comes ten years after the first such
The 30-week long trial, dubbed Sustain 9, assessed the efficacy and safety of Ozempic injection 1.0 mg in combination with the SGLT-2 inhibitors against placebo. The drug was
Fedratinib is a highly selective JAK2 inhibitor intended for the treatment of patients with myelofibrosis, a serious bone marrow disorder that disrupts the body’s normal production of blood
The data, part of a broader ongoing 52 week Phase III study in 543 patients, show 97.7% of patients treated with Cosentyx 300mg achieved PASI 75 and 80.9%
Also known as RPL554, ensifentrine, is being investigated as an inhaled dual inhibitor of the phosphodiesterase 3 and 4 enzymes and is designed to have bronchodilator and anti-inflammatory
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.